for males ages 18-25 (full criteria)
healthy people welcome
at UC Davis
study started
estimated completion
Keith Baar, PhD(ucdavis)



This study will investigate the effects of dietary supplementation of epicatechin-rich cocoa in humans on collagen synthesis and power-based performance outcomes (rate of force development).

Official Title

Determining an Optimal Dose of Epicatechin-Rich Chocolate and Its Effect on Performance


The investigators have recently completed a study looking at the expression of the collagens following consumption of increasing doses of epicatechin in rats . This data clearly shows that increasing doses of epicatechin, either 0.5 delivered once, twice, or three times a day, or 2 once a day, results in increasing expression of the fibrillar collagens (I, III, and V). This preliminary data suggests that epicatechin-rich chocolate supplementation can increase collagen expression in humans and that this may improve force transfer. From this background, the hypothesis proposed is that supplementation with epicatechin-rich chocolate will increase rate of force development and performance in athletes. Therefore, this simple nutrition intervention has the potential to simultaneously improve performance, decrease injuries and accelerate return to competition through improved collagen synthesis.


Collagen Synthesis Epicatechin-rich cocoa dose response Epicatechin Dose Response Epicatechin-rich cocoa on performance


You can join if…

Open to males ages 18-25

  • Collegiate level male athletes between the ages of 18¬-25 years of age, currently participating in sport, will be recruited to participate in the study.

You CAN'T join if...

  • History of more than 3 musculoskeletal injuries within the past 12 months.
  • Health and dietary restriction (e.g. lactose intolerance) that would be affected by the supplementation protocol.
  • The initial phase will be performed in males since collagen synthesis varies significantly throughout the menstrual cycle in females. Since collagen synthesis is the main outcome measure for the study this would confound the initial phase of the work. Provided this work proves successful then the investigators will aim to proceed with similar research in females.


  • Neurobiology, Physiology & Behaviour accepting new patients
    Davis California 95616 United States

Lead Scientist

  • Keith Baar, PhD (ucdavis)
    Professor, Neurobiology, Physiology and Behavior. Authored (or co-authored) 123 research publications


accepting new patients
Start Date
Completion Date
University of California, Davis
Study Type
Last Updated